Nugent Katie L, Spahr Erin, Toroney Jaimie, Mojtabai Ramin, Nettles Carrie, Turner Lydia W, Fenton Ashley, Spivak Amethyst, Cullen Bernadette A, Everett Anita, Eaton William W
From the *Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine; †Community General Psychiatry Division, Johns Hopkins Bayview Medical Center; ‡Department of Medical Informatics, Kennedy Krieger Institute; §Department of Mental Health, Johns Hopkins Bloomberg School of Public Health; ∥Laboratory for Neurocognitive Imaging Research, Kennedy Krieger Institute, Baltimore, MD; ¶The Lewin Group, Falls Church VA; #School of Nursing, Johns Hopkins University; **Francis King Carey School of Law, University of Maryland; and ††Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
J Clin Psychopharmacol. 2015 Jun;35(3):324-8. doi: 10.1097/JCP.0000000000000311.
The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety of included adverse effects or are not practical for use in most clinical or research settings owing to specialized rater training required and administration length. This report describes a modification of the Monitoring of Side Effects Scale (MOSES), an established adverse effect rating scale, by adding severity anchors to improve its reliability and ease of use. Interrater reliability was good for 7 of the 8 bodily adverse effects assessed, with intraclass correlation coefficients ranging from 0.76 to 0.91 in a sample of patients with severe mental illness. This modified version of the Monitoring of Side Effects Scale holds promise as a useful tool for assessing medication adverse effects in clinical and research settings.
在临床和研究环境中，评估精神科药物的不良反应非常重要，因为这些不良反应常与停药、症状加重及生活质量下降相关。目前可用的评估工具，要么在涵盖的不良反应数量和种类方面存在局限，要么由于需要专门的评估者培训且耗时较长，在大多数临床或研究环境中不实用。本报告描述了对既定的不良反应评定量表“副作用监测量表（MOSES）”的一种改进，即增加严重程度锚点以提高其可靠性和易用性。在一组重症精神疾病患者样本中，所评估的8种身体不良反应中有7种的评定者间信度良好，组内相关系数在0.76至0.91之间。这种改进版的副作用监测量表有望成为临床和研究环境中评估药物不良反应的有用工具。
